Biomarkers and Mortality in ST-Segment Elevation Myocardial Infarction

Pedro Pimenta de Mello Spineti1,2
Hospital Universitário Pedro Ernesto,1 Rio de Janeiro, RJ - Brazil
Hospital Unimed - Rio,2 Rio de Janeiro, RJ - Brazil

Biomarkers have been increasingly used in non-ST-segment elevation acute coronary syndromes (NSTE-ACS) for diagnosis, stratification, and short-and long-term prognosis.1 However, they play a less decisive role in ST-segment elevation myocardial infarction (STEMI) where ST-segment elevation in ECG remains the most important tool for diagnosis and treatment decision.2

Troponin has been the most widely used biomarker to evaluate the prognosis in STEMI,1 but other biomarkers may also be used to assess the potential causes and complications of myocardial infarction (MI).3 High sensitivity C-reactive protein (hs-CRP) is substantially increased in STEMI as a result of the inflammatory response to myocyte necrosis, and is associated with the subsequent risk for death or heart failure.4-6 Natriuretic peptides reflect the hemodynamic impact of MI and are associated with its prognosis.7 Although both natriuretic peptides and CRP enhance risk assessment, no clear guidance is available on how to direct specific therapeutic maneuvers in the setting of STEMI based on these biomarkers.3

Damman et al.8 studied the role of multiple biomarkers in a large cohort of STEMI patients. Glucose, estimated glomerular filtration rate (eGFR), and N-terminal pro-brain natriuretic peptide (NT-ProBNP), but not hs-CRP were the strongest predictors for long-term mortality in 1,034 STEMIs.8

Correia and Esteves9 performed a systematic review and meta-analysis on C-reactive protein and outcomes in acute coronary syndromes. After literature review, 19 articles were included in the study, most of them addressing NSTEMI and unstable angina. In the analysis of short-term outcomes, nine studies were positive and six were negative, with an overall OR of 1.65 (95% CI: 1.2-2.3). Nevertheless, overall multivariate OR of short-term follow-up was not obtained, since this measurement was described only in three heterogeneous studies. Only two short-term studies analyzed the incremental predictive value of CRP in relation to multivariate models, with contrasting results.

A study published in this issue by Milano et al.10 addresses the role of hs-CRP on in-hospital mortality in a single center in Brazil. A total of 118 patients admitted for STEMI in the emergency department or cardiac intensive care unit were included in a retrospective cohort study. Serum hs-CRP was measured at admission. Twenty patients (16.9%) died during hospitalization. Admission hs-CRP levels were higher among the patients who died (median 10.47 [IQR 23.99]) compared with those who survived (median 2.13 [IQR 5.66]). Binary logistic regression analysis revealed that in-hospital death was independently associated with higher concentration of hs-CRP and older age. A one-unit increase in hs-CRP increased the risk of death by 15%, after adjustment for established risk factors.

The research question studied by Milano et al.10 seems relevant and the results contribute to the knowledge on prognostic factors in STEMI. However, the study has limitations and the results should be interpreted with caution. It was a single-center retrospective study with a small sample, which could limit its external validity. In addition, the study did not establish a cut-off point for hs-CRP levels in relation to mortality, making it hard to interpret the assay results in clinical practice. The multivariate model did not include other known prognostic variables such as the Killip class,11 MI location, time to treatment, and cardiac arrest at admission. Also, the authors did not analyze the incremental value of hs-

Keywords

ST- Elevation Myocardial Infarction /mortality; Biomarkers; C Reactive Protein.
CRP to usual prognostic score systems in STEMI, such as GRACE\textsuperscript{12} and TIMI Risk\textsuperscript{13} scores. Another major issue is the absence of new treatments directly addressing hs-CRP in STEMI.\textsuperscript{3}

Despite these biases and limitations, we believe the study has some merits. The findings suggest that hs-CRP levels can be used as a measure of inflammatory response to myocardial ischemia after STEMI, which could lead to a more personalized prognosis and therapy to improve the outcome in this population. Prospective and larger cohort studies are needed to confirm these findings and to establish a cut point for a wider clinical use of this tool. Randomized controlled trials are needed to establish the effectiveness of new treatment regimens guided by biomarkers in STEMI.

References


